Business Wire

Kx Systems: Kdb+ Powers Trading Platform for BitMEX High-Frequency Bitcoin Exchange

Share

Kx Systems, a subsidiary of First Derivatives plc (FD), and provider of the industry-leading kdb+ time series database, announces that Bitcoin Mercantile Exchange (BitMEX), a cryptocurrency derivatives exchange, has expanded its use of kdb+ within its trading platform.

Kdb+ is widely used in the financial services industry to power trading and risk management platforms, setting industry records for speed, performance and stability in high performance applications. These attributes are increasingly recognized across a range of markets requiring fast analytics on Big Data, such as manufacturing and retail, while Kx is also at the forefront of the use of predictive analytics, virtual reality, artificial intelligence and machine learning techniques.

BitMEX is a trading venue where all deposits and withdrawals happen on the Bitcoin blockchain. Started in 2014, current trading volume exceeds US$3,500,000,000 per month of derivatives products. The firm’s founders have experience in equities derivatives trading, algorithmic trading systems and high-performance web applications. Building on the foundation of their experience creating market making and high frequency trading systems with kdb+, the engineers at BitMEX are continuously expanding their offerings.

Arthur Hayes, CEO of BitMEX said: “With kdb+ we can dynamically change and add new features and bring new products to market within two hours. Having this speed gives us a significant edge. Another advantage to using kdb+ is we know that our numbers are correct all of the time. This is important when you are dealing with lots of leverage and other technologies. We can be confident to offer high leverage because we have audited, reliable results. Our competitors can barely do these calculations within the day, they go offline to do this.”

Mark Sykes, COO at Kx Systems said: "We are increasingly seeing kdb+ being used for streamed event processing and in-memory analytics, as well as more traditional time-series storage. BitMEX’s extraordinary growth, cementing them as the world's most advanced derivatives exchange for virtual currencies, tracks with their expanded use of Kx software, perfectly illustrating how our technology is transforming new markets. We look forward to working closely with BitMEX as they continue writing their success story."

About FD and Kx

FD is a global technology provider with 20 years of experience working with some of the world’s largest finance, technology and energy institutions and employs over 1,700 people worldwide. The Group’s Kx technology is a leader in high-performance, in-memory computing, streaming analytics and operational intelligence. It delivers the best possible performance and flexibility for high-volume, data-intensive analytics and applications for multiple industries including finance, pharmaceuticals and manufacturing.

About BitMEX

BitMEX gives retail investors access to the global markets using digital currencies and derivatives. BitMEX through the use of digital currency derivatives aims to allow anyone, anywhere, to trade any type of financial asset. BitMEX will allow the 90% of the world, who are not serviced by traditional financial services firms, access to financial products. The exchange allows for trading using up to up to 100x leverage on Bitcoin and other Altcoins. BitMEX is now the world’s largest Bitcoin / USD and digital currency derivatives trading platform by volume.

For more information about Kx please visit www.kx.com. For general enquiries, write to info@kx.com.

For more information about BitMEX please visit www.bitmex.com.

Kx® and kdb+ are registered trademarks of Kx Systems, Inc., a subsidiary of First Derivatives plc. © 2017 Kx Systems

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

For further information please contact:
Octopus Group for Kx Systems
Micky Izelaar
kxSystems@octopusgrp.com
0845 370 7024

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

New Data From Landmark HELIOS-B Phase 3 Study Presented at ESC Congress 2025 Demonstrate Vutrisiran’s Long-Term Cardiovascular Benefit in ATTR-CM31.8.2025 12:15:00 EEST | Press release

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced results of new analyses from the HELIOS-B Phase 3 study of AMVUTTRA® (vutrisiran), an RNAi therapeutic approved for the treatment of the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults. Data from the 12-month follow-up of the ongoing open-label extension (OLE) period of HELIOS-B were presented during an oral session at the European Society of Cardiology (ESC) Congress 2025 held in Madrid, Spain. These data reflect outcomes of treatment through up to 48 months, including the initial double-blind period of 33-36 months, and highlight the ongoing clinical benefit of vutrisiran, which causes rapid knockdown of the disease-causing transthyretin (TTR) protein, including a 37% risk reduction in the composite endpoint of all-cause mortality (ACM) or first cardiovascular (CV) event in the overall population (p<0.001) and a 42% risk reduction in th

WETEX Opens Broad Investment Horizons for International Companies31.8.2025 09:30:00 EEST | Press release

Under the directives of HH Sheikh Mohammed bin Rashid Al Maktoum, Vice President and Prime Minister of the UAE and Ruler of Dubai, and the patronage of HH Sheikh Ahmed bin Saeed Al Maktoum, Chairman of the Dubai Supreme Council of Energy, Dubai Electricity and Water Authority (DEWA) will organise the 27th edition of the Water, Energy, Technology and Environment Exhibition (WETEX) from 30 September to 2 October 2025 at the Dubai World Trade Centre. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250830023664/en/ WETEX opens broad investment horizons for international companies (Photo: AETOSWire) WETEX embodies the UAE's pioneering position in clean and renewable energy and sustainability. It also supports Dubai's ambitious vision of a sustainable economy. The exhibition covers multiple areas including water, energy, smart cities, green mobility, artificial intelligence and digital transformation. “WETEX reflects the UAE's unwa

Daiichi Sankyo Announces the Initiation of the Development of Oral Triple Combination Lipid-Lowering Tablets to Support the Management of LDL-C30.8.2025 19:00:00 EEST | Press release

Daiichi Sankyo Europe is pleased to announce the initiation of the development of new oral triple combination tablets in Europe of bempedoic acid, ezetimibe, and different doses of a statin (atorvastatin or rosuvastatin), with the potential to lower low-density lipoprotein cholesterol (LDL-C) levels.9 It is well known that combination therapies reduce the pill burden for patients, potentially enhancing treatment adherence and facilitating treatment with a goal of improving cardiovascular outcomes.9,10 “As bempedoic acid and ezetimibe are already approved as a single-dose therapy, the development of an oral triple combination tablet with different doses of a statin, can make it easier for physicians to tailor treatment to the individual needs of each patient,” says Dr. Stefan Seyfried, Vice President and Head Medical Affairs Specialty Medicines, Daiichi Sankyo Europe. “This approach exemplifies our dedication to our motto: ‘we care for every heartbeat’.” “The management of dyslipidaemia

Alnylam to Advance Zilebesiran into Global Phase 3 Cardiovascular Outcomes Trial30.8.2025 17:30:00 EEST | Press release

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced plans to initiate a Phase 3 cardiovascular outcomes trial (CVOT) to evaluate the potential of zilebesiran to reduce the risk of major adverse cardiovascular events. This decision is informed by results from the comprehensive KARDIA Phase 2 program, including KARDIA-3 results presented today as a late-breaking abstract at the European Society of Cardiology (ESC) Congress in Madrid, Spain. Zilebesiran is an investigational subcutaneously administered RNAi therapeutic which, in the KARDIA Phase 2 program, has shown reductions in blood pressure by targeting liver-expressed angiotensinogen (AGT), the most upstream precursor in the Renin-Angiotensin-Aldosterone System (RAAS), which plays a key role in blood pressure regulation and impacts cardiovascular and renal health. KARDIA-3, the third Phase 2 study in the KARDIA program, evaluated the efficacy and safety of zilebesiran in patients with

BeOne Medicines Announces Positive Topline Results for Sonrotoclax in Relapsed or Refractory Mantle Cell Lymphoma (MCL)29.8.2025 13:00:00 EEST | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced positive topline results from a Phase 1/2 study (BGB-11417-201) of sonrotoclax, a next-generation and potentially best-in-class investigational BCL2 inhibitor, in adult patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL), following treatment with a Bruton’s tyrosine kinase inhibitor (BTKi) and anti-CD20 therapy. BeOne plans to present the full data at an upcoming medical meeting. “For people with relapsed or refractory mantle cell lymphoma, the disease is aggressive, the treatment landscape fragmented, and the outcomes unacceptably poor. These topline results for sonrotoclax underscore its potential to deliver meaningful and durable responses and offer the first BCL2 inhibitor for patients with R/R MCL, if approved,” said Lai Wang, PhD, Global Head of R&D, BeOne Medicines. “These data add to the remarkable progress we’ve seen over the past five years in treating B-cel

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye